DexCom Inc - רווח נקי למניה בארבעת הרבעונים האחרונים DXCM

The fierce battle for leadership in sensor technologies requires colossal R&D expenditures, which impacts the 12-month YoY EPS trend, where the current mark is 40.60. Stability provides DexCom, Inc. (DXCM) immunity to trade wars, while a strong talent pool of equity-motivated bioengineers guarantees the development of innovative gadgets for diabetics.

Year-over-year (YoY) EPS growth (TTM) measures the rate of change in net income per share over a rolling twelve-month period. By analyzing the annual dynamics of the EPS TTM figure, an investor assesses the efficiency of profit generation relative to past results. This metric is calculated as the percentage deviation of the current earnings value from the same window of the previous year. For DexCom, Inc. (DXCM), this indicator is critical when assessing the impact of price wars and new weight-loss drugs on business profitability.